Eflornithine plus Nifurtimox combination therapy

TERMINATED · PHASE2, PHASE3 · Trypanosomiasis, African

Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.